Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $547.49, for a total transaction of $5,201,155.00. Following the completion of the sale, the chief executive officer owned 40,513 shares of the company’s stock, valued at approximately $22,180,462.37. The trade was a 19.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $544.10 on Thursday. The firm has a 50-day simple moving average of $568.19 and a 200 day simple moving average of $520.67. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $609.35. The stock has a market cap of $23.10 billion, a PE ratio of 20.08, a PEG ratio of 1.80 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). The company had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm’s quarterly revenue was down 1.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $6.63 EPS. Research analysts forecast that United Therapeutics Corporation will post 26.84 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of UTHR. Torren Management LLC bought a new position in shares of United Therapeutics in the fourth quarter valued at approximately $26,000. Activest Wealth Management raised its stake in shares of United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 56 shares during the last quarter. WealthCollab LLC raised its stake in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 38 shares during the last quarter. Rakuten Securities Inc. raised its stake in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 46 shares during the last quarter. Finally, Entrust Financial LLC bought a new position in shares of United Therapeutics in the fourth quarter valued at approximately $31,000. Institutional investors own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on UTHR shares. Cantor Fitzgerald raised their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. TD Cowen restated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. UBS Group raised their price target on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research note on Thursday, March 5th. Finally, Royal Bank Of Canada cut their price target on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $619.42.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.